Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Novartis To Launch Five New Biosimilar Drugs By 2020

XTALKS VITALS NEWS

Biosimilar

The company says that the expansion will further reaffirm Sandoz’s commitment to providing less expensive versions of biologic drugs.

Share this!

June 21, 2016 | by Sarah Massey, M.Sc.

Novartis’ generics division, Sandoz, has announced that it plans to push five new biosimilar drugs through the product pipeline all the way to approval by 2020. The company says that the expansion will further reaffirm Sandoz’s commitment to providing less expensive versions of biologic drugs.

Tweet: Novartis’ Sandoz to push five new #biosimilar drugs to approval by 2020 http://ctt.ec/sLUV9+

Sandoz has plans to file applications for marketing approval for 11 biosimilar drugs in both the US and in Europe, by the end of 2017. The company has already reached the half-way point by filing six of the 11 biosimilar applications.

Sandoz’s current biosimilar offerings include Omnitrope (somatropin) and Binocrit (epoetin alfa) in Europe, and Zarxio (filgrastim-sndz) in the US. If all of the company’s biosimilar applications are approved by regulatory agencies, Sandoz may have nearly three times as many products on the market in just four years.

Novartis has also pledged to spend $1 billion on biosimilar manufacturing between 2010 and 2020. In the past six years, the company has already expanded operations at its manufacturing plants in Schaftenau and Kundl, Austria.

Biosimilars are the generic versions of biologic drugs, and are considered to have clinically comparable effects as their branded counterpart. Once the patent-exclusivity period for a given biologic has expired, biosimilars companies are free to develop less-expensive, copy-cat versions.



Investment into biosimilars has been spurred on by the recent patent expirations for top-selling biologics, including Humira and Remicade. While many biosimilars have been long-established on the European market, the US is only just starting to enter the space.

Novartis' Zarxio – a biosimilar of Amgen’s biologic drug, Neupogen – was the first ever biosimilar to win US Food and Drug Administration (FDA) approval in 2015. The regulatory agency has since approved a Remicade biosimilar developed by Celltrion and Pfizer.

Novartis plans to release biosimilar versions of Enbrel, Humira, Neulasta, Remicade, and Rituxan over the next few years. In 2015, those five biologics generated $44 billion in worldwide revenue.

“Biologics have revolutionized treatment of many disabling and life-threatening diseases but far too many people who need these medicines are not able to access them,” said Richard Francis, CEO of Sandoz. “At Sandoz, we are committed to significantly broadening patient access to biologics with a series of major biosimilar launches over the next few years.”


Keywords: Biosimilar, Biologic, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.